Details of the Drug

General Information of Drug (ID: DMN32UV)

Drug Name
RZ358
Indication
Disease Entry ICD 11 Status REF
Congenital hyperinsulinism 5A4Y Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DJM3W0

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin receptor (INSR) TTCBFJO INSR_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Congenital hyperinsulinism
ICD Disease Classification 5A4Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Insulin receptor (INSR) DTT INSR 1.03E-05 0.26 0.66
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04538989) An Open-Label Multiple-Dose Study of RZ358 in Patients With Congenital Hyperinsulinism. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Rezolute